Research & Development: Page 27
-
Stock via Getty Images
ProfileHow Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'
Why sexual health and telemedicine are key to the company's goals in oncology.
By Meagan Parrish • Feb. 16, 2022 -
Stock via Getty Images
How a 'powerful form' of data capture is transforming pharma labs
AnIML, an open data format, is helping the industry build labs of the future.
By Robin Robinson • Feb. 15, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Stock via Getty Images
OpinionIndustry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Permission granted by Mike Rea.
Q&AInnovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Courtesy of Saniona
Q&ASaniona's CEO on why it takes a village to develop treatments for a rare disease
Saniona built its village by first hiring a head of patient advocacy.
By Kim Ribbink • Feb. 8, 2022 -
Retrieved from Google image.
Q&AGaining real-world results from a decentralized trial
Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.
By Kelly Bilodeau • Feb. 8, 2022 -
Courtesy of 23andMe
Q&AWhy 23andMe's first solo clinical trial is a big deal
It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come.
By Taren Grom • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Permission granted by Datacubed Health
Sponsored by Datacubed HealthSafety Monitoring: What does ePRO have to do with it?
Safety monitoring is critical to clinical trials. Learn how ePRO can play a role. Read the article.
Feb. 7, 2022 -
Courtesy of Web Sun
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Permission granted by Mary Harmon
Q&APTC's vice president of patient relations outlines the importance of patient input in rare disease R&D
You can't know what matters to rare disease patients unless you ask them.
By Kim Ribbink • Feb. 3, 2022 -
Permission granted by Peter Anastasiou
Q&A // First 90 DaysNew Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
By Taren Grom • Feb. 3, 2022 -
Ricardo Ceppi via Getty Images
OpinionBiopharma's R&D leaders on how technology can accelerate drug development
How emerging digital tools are providing enhanced clinical insights and improved trial results.
By Taren Grom • Jan. 27, 2022 -
Courtesy of Sanofi
Q&ASanofi's chief scientist on why 'this is the moment' for AI in Big Pharma
How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development.
By Meagan Parrish • Jan. 27, 2022 -
Justin Sullivan via Getty Images
Q&AWith its wealth of patient data, Walgreens is looking to disrupt the clinical trial space
How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.
By Taren Grom • Jan. 26, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Janssen's Dr. Sylvie Laquerre
Why following the science is crucial when bringing new compounds to market.
By Taren Grom • Jan. 26, 2022 -
How AI is helping pharma solve some of its COVID problems
With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.
By Meagan Parrish • Jan. 25, 2022 -
Permission granted by Craig Lipset
ProfileOne man's quest to boost the patient's role in clinical trials
How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.
By Robin Robinson • Jan. 24, 2022 -
Retrieved from Google image.
OpinionLeaders predict improving patient engagement will lead to growth opportunities
Why patient engagement is key to successful business growth.
By Taren Grom • Jan. 24, 2022 -
Retrieved from Google image.
ProfileEvofem CEO Saundra Pelletier aims to level the playing field between men's and women's health
Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.
By Alexandra Pecci • Jan. 23, 2022 -
Space Frontiers via Getty Images
ProfileVaxxinity looks to pioneer the next revolution in pharma
With a one-of-a-kind platform and novel candidates for major indications, Vaxxinity wants to disrupt the industry’s paradigm of success.
By Meagan Parrish • Jan. 14, 2022 -
Retrieved from Google image.
Opinion
Pharma execs reveal the industry's most pressing issues
Several market factors — including COVID — are driving changes and trends in the industry.
By Taren Grom • Jan. 14, 2022 -
Diego Camargo/PharmaVoice
Welcome to the new PharmaVoice
A similar mission, a new format, and our plans for PharmaVoice's next chapter.
By Davide Savenije • Jan. 13, 2022 -
Dan Kitwood via Getty Images
5 trends shaping clinical trial regulations in 2022
As agencies respond to innovations in pharma, notable shifts in 2022 are on the way.
By Meagan Parrish • Jan. 11, 2022 -
[photo]. Retrieved from Ovid Therapeutics.
Q&AOvid's CEO shares his vision for rare disease developments
Jeremy Levin, chairman and CEO of Ovid Therapeutics discusses the keys to success in rare disease innovation.
By Kim Ribbink • Jan. 10, 2022
Previous
